Local News

Biogen Signs Neuro Disease Drug Deal with Cambridge Startup

By January 13, 2020No Comments

A young biotech startup hoping to map out the actions of cells throughout the body has signed its second major drug development partner with industry giant Biogen.

Biogen (Nasdaq: BIIB) will pay Cambridge’s Camp4 Therapeutics $15 million upfront to help develop new therapies for neurological and neurodegenerative diseases. The deal could also earn Camp4 as much as $96 million in development and milestone payments for each initial drug target and $173 million for each additional target.

Camp4 declined to disclose how many initial targets are laid out in the deal terms, and what diseases the two companies are interested in treating.

The collaboration reunites Biogen with Camp4 CEO Josh Mendel-Brehm, who spent nearly four years working on gene therapy programs and M&A at Biogen.

Camp4 launched in May 2018 with $30 million from Polaris Partners, technology entrepreneurs Marc Andreessen and Ben Horowitz’s investment firm and The Kraft Group.